Abstract In the recent past, pharmaceutical expenditure has been steadily increasing, but the productivity of the sector - measured as the number of New Molecular Entities (NMEs) has been decreasing. In this chapter we review and analyse the price regulation policies that are currently used by regulators worldwide and we will describe the salient features of these policies from a public health point of view. We will also discuss this in terms of their impact on innovation
Pharmaceuticals account for almost a fifth of total health spending in OECD-countries. Both pharmace...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
In the recent past, pharmaceutical expenditure has been steadily increasing, but the productivity of...
This paper provides a brief review of the economics of information and patents and an explanation of...
The debate on drug prices has reached new heights with the controversy around the role of prices in ...
As rising health care expenditures focus government attention on slowing the growth, the pharmaceuti...
As rising health care expenditures focus government attention on slowing the growth, the pharmaceuti...
An explosion of knowledge and a growing array of tools and technologies have transformed modern drug...
Our paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical ...
Our paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical ...
This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK...
The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gro...
This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK...
The empirical relationship between pharmaceutical industry revenues and pharmaceutical industry inno...
Pharmaceuticals account for almost a fifth of total health spending in OECD-countries. Both pharmace...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
In the recent past, pharmaceutical expenditure has been steadily increasing, but the productivity of...
This paper provides a brief review of the economics of information and patents and an explanation of...
The debate on drug prices has reached new heights with the controversy around the role of prices in ...
As rising health care expenditures focus government attention on slowing the growth, the pharmaceuti...
As rising health care expenditures focus government attention on slowing the growth, the pharmaceuti...
An explosion of knowledge and a growing array of tools and technologies have transformed modern drug...
Our paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical ...
Our paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical ...
This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK...
The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gro...
This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK...
The empirical relationship between pharmaceutical industry revenues and pharmaceutical industry inno...
Pharmaceuticals account for almost a fifth of total health spending in OECD-countries. Both pharmace...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...